Uncover key drivers, emerging technologies, and competitive movements shaping the positron emission tomography (pet) nuclear medicine market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Positron Emission Tomography (PET) Nuclear Medicine Market between 2026 and 2030?

The positron emission tomography (pet) nuclear medicine market has witnessed substantial expansion in recent years. Its valuation is anticipated to climb from $13.16 billion in 2025 to $15.06 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.5%. This growth observed in the past can be credited to various elements, such as rising cancer diagnosis rates, the expansion of nuclear medicine facilities, the widespread application of f-18 radiotracers, an increase in cardiology imaging uses, and enhancements in radiopharmaceutical production.

The positron emission tomography (PET) nuclear medicine market is anticipated to experience swift expansion over the next few years. It is projected to reach $25.7 billion by 2030, with a compound annual growth rate (CAGR) of 14.3%. This projected growth can be attributed to increased investments in molecular imaging, escalating demand for personalized medicine diagnostics, the widening scope of neurological imaging applications, progress in radiotracer development, and the increasing adoption of hybrid imaging systems. Significant trends expected during this period include the broader acceptance of advanced radiotracers, the expanding application of PET imaging in oncology, increasing integration of PET with CT and MRI systems, the diversification of precision diagnostic imaging applications, and a heightened focus on early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19151&type=smp

Which Drivers Are Expected To Impact The Positron Emission Tomography (PET) Nuclear Medicine Market During The Forecast Period?

The positron emission tomography (PET) nuclear medicine market is expected to grow due to the increasing prevalence of chronic diseases. A chronic disease is characterized as a long-term health condition that typically lasts for three months or more, potentially requiring ongoing medical attention or restricting daily activities. The escalation in chronic diseases is attributed to factors such as an aging population, inadequate physical activity, poor eating habits, and environmental risks. PET nuclear medicine supports the management of chronic diseases by offering advanced imaging methods that enable their early detection, precise diagnosis, and continuous monitoring. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, which signifies a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of chronic diseases acts as a driving force for the positron emission tomography (PET) nuclear medicine market’s growth.

How Is The Positron Emission Tomography (PET) Nuclear Medicine Market Divided Into Segments?

The positron emission tomography (pet) nuclear medicine market covered in this report is segmented –

1) By Type: F-18, Rb-82, Other Types

2) By Procedure: Diagnostic Procedures, Hybrid PET CT Procedures, Positron Emission Tomography Procedures, Therapeutic Procedures, Beta Emitter Procedures, Alpha Emitter Procedures, Targeted Radiopharmaceutical Therapy

3) By Application: Oncology, Cardiology, Neurology, Other Applications

4) By End User: Hospitals, Diagnostic Centers, Research Institutes

Subsegments:

1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose), F-18 NaF (Sodium Fluoride), F-18 Fluorocholine

2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging, Rb-82 for Cardiac PET Stress Testing, Rb-82 for Other Cardiac Applications

3) By Other Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Ga-68 (Gallium-68)

How Are Emerging Trends Affecting The Progression Of The Positron Emission Tomography (PET) Nuclear Medicine Market?

Leading companies in the positron emission tomography (PET) nuclear medicine market are developing sophisticated products, such as PET slice scanners, to provide highly detailed images of metabolic functions. A PET slice scanner is a medical imaging device that combines positron emission tomography (PET) with advanced computing methods to create intricate, cross-sectional images of metabolic processes within the body, facilitating the detection and monitoring of diseases, especially cancer. For example, in July 2024, Positron Corporation, a US-based nuclear medicine firm, launched the NeuSight PET-CT 3D 64-slice scanner. The NeuSight PET-CT 3D 64-slice scanner establishes a new standard in imaging and diagnostic accuracy, integrating advanced technology with patient comfort and operational efficiency. It is designed to transform cardiac PET imaging and offers exceptional value and performance at an unparalleled price point, making it an ideal choice for cardiology and oncology clinical studies. Equipped with superior data acquisition and innovative identification technology, the NeuSight PET-CT improves scanning speed and precision, delivering comprehensive anatomic and functional imaging for studies of the heart, tumors, and brain across numerous molecular imaging applications.

Which Major Firms Are Strengthening Their Position In The Positron Emission Tomography (PET) Nuclear Medicine Market?

Major companies operating in the positron emission tomography (pet) nuclear medicine market are Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Shimadzu Corporation, Toshiba America Medical Systems Inc., Mediso Medical Imaging Systems Ltd., Lantheus Holdings Inc., Jubilant DraxImage Inc., Advanced Accelerator Applications, Eckert & Ziegler Strahlen- und Medizintechnik AG, Cardinal Health, NorthStar Medical Radioisotopes LLC, Bruker Corporation, Digirad Corporation, Neusoft Medical Systems Co. Ltd., Agfa HealthCare NV, Bayer AG, Positron Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/positron-emission-tomography-pet-nuclear-medicine-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Positron Emission Tomography (PET) Nuclear Medicine Market?

North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) nuclear medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Positron Emission Tomography (PET) Nuclear Medicine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19151&type=smp

Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Nuclear Medicine Market 2026, By The Business Research Company

Nuclear Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report

Poc Medical Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/poc-medical-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model